Barbara Davis Center

University of Colorado Anschutz Medical Campus

University of Colorado Anschutz Medical Campus
1775 Aurora Ct
Aurora, CO 80045
United States
Call 303-724-0064 Email this location
The Barbara Davis Center is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Peter Gottlieb, MD, the TrialNet team at the Barbara Davis Center is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.  

Our Team

Principal Investigators 
Dr. Gottlieb’s research focuses on understanding the cause of autoimmunity which leads to type 1 diabetes and other related diseases. He has focused on learning about different components of the immune system which may contribute to disease development. As a logical extension of this basic science work, he has been involved in clinical trials in prediabetes and new and recent onset type 1 diabetes patients for 15 years. He has been the principal investigator in investigator-initiated as well as multicenter trials and participates in trial networks such as Type 1 Diabetes TrialNet.
Dr. Steck’s primary research focus is in the area of epidemiology, prediction and prevention of type 1 diabetes. She has a background in pediatric endocrinology, with specific training and expertise in pediatric diabetes. Her research projects include epidemiological studies such as DAISY (Diabetes Autoimmunity Study in the Young), TEDDY (The Environmental Determinants of Diabetes in the Young), the Twin Family and TrialNet studies.
Dr. Michels laboratory at the Barbara Davis Center for Diabetes is focused on studying the immunology of autoimmune diseases, with a particular focus on type 1 diabetes. Having lived with type 1 diabetes for the more than 20 years, it is Dr. Michels career goal to contribute to the prevention and ultimately a cure for the disease. Currently, type 1 diabetes is a predictable disease with the measurement of antibodies directed against proteins from the beta cell; however it is not yet a preventable disease. His basic and translational research focuses on understanding the underlying immunology of diabetes and how human leukocyte antigen alleles confer disease risk and protection.
Research Coordinators 
Team Manager
Regulatory Manager
Research Coordinator
Research Coordinator
Research Coordinator
Research Coordinator
Research Coordinator
Soňa Seligova
Research Coordinator

Regional Affiliates


Kaiser Permanente Colorado
1960 North Ogden Street, Denver, CO 80218

Las Vegas

1707 E. Charleston Blvd. Suite 230, Las Vegas, NV 89102

Salt Lake City

University of Utah
50 N Medical Drive,, Salt Lake City, UT 84132


Regional West Health Services
3911 Ave. B, Suite 1110, Scottsbluff, NE 69361

South Ogden

Advanced Research Institute
6028 South Ridgeline Drive, South Ogden, UT 84405

St. Louis

Washington University
660 S. Euclid, St. Louis, MO 63110

Tripler Army Medical Center

Tripler Army Medical Center
1 Jarrett White Rd, Tripler Army Medical Center, HI 96859

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study

Abatacept - Closed to Enrollment - Study Ongoing

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.


Teplizumab (Anti-CD3)

We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.


Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.